Lung Cancer Biomarkers | Delta-like Ligand 3 (DLL3)
As an important target for SCLC and other tumors, multiple therapies developed around DLL3 have developed rapidly in recent years. DLL3 drugs with bispecific antibodies, monoclonal antibodies, antibody-conjugated drugs (ADC), cell therapy, and bispecific T-cell bonding agents (BiTE) have made clinic
2023/04/20 Read: 2562